Last edited by Vijora
Sunday, July 26, 2020 | History

2 edition of Pharmaceutical perspectives of cancer therapeutics found in the catalog.

Pharmaceutical perspectives of cancer therapeutics

Lu, Yi Ph. D.

Pharmaceutical perspectives of cancer therapeutics

by Lu, Yi Ph. D.

  • 250 Want to read
  • 4 Currently reading

Published by Springer, AAPS Press in Dordrecht, New York, [Arlington, Va.] .
Written in English

    Subjects:
  • Chemotherapy,
  • Antineoplastic agents,
  • Cancer

  • Edition Notes

    Includes bibliographical references and index.

    StatementYi Lu, Ram I. Mahato, editors
    Classifications
    LC ClassificationsRC271.C5 P4763 2009
    The Physical Object
    Paginationxvi, 693 p. :
    Number of Pages693
    ID Numbers
    Open LibraryOL25304141M
    ISBN 109781441901309, 9781441901316
    LC Control Number2009927127

      The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related mortality in the Cited by: A comprehensive review of contemporary antisense oligonucleotides drugs and therapeutic principles, methods, applications, and research. Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, Format: Hardcover.

    Category: MEDICAL BOOKS. May 3, Prostate Cancer Imaging: An Engineering and Clinical Perspective This book covers novel strategies and state of the art approaches for automated non-invasive systems for early prostate cancer diagnosis. Prostate cancer is the most frequently diagnosed malignancy after skin cancer and the second leading. Book Chapters. 1. Cheng K, Qin B. RNA interference for cancer therapy, in Pharmaceutical Perspectives of Cancer Therapeutics (Eds. Lu Y, Mahato R), AAPS-Springer publishing program 2. Qin B, Shukla RS, Cheng K. Delivery of nucleic acids for ocular gene modulation, in Advances in Ocular Drug Delivery (Ed. Mitra AK), Research Singpost.

      Gold nanoparticles bearing functional anti-cancer drug and anti-angiogenic agent: a ‘2 in 1’ system with potential application in cancer therapeutics. J. Biomed. Nanotechnol. 1(2), – ().Crossref, CAS, Google Scholar; Arvizo RR, Rana S, Miranda OR, Bhattacharya R, Rotello VM, Mukherjee by: 9. Title:Synthetic Lethality-Based Therapeutics: Perspectives for Applications in Colorectal Cancer VOLUME: 12 ISSUE: 4 Author(s):D. Soncini, I. Caffa, F. Patrone, A Cited by: 5.


Share this book
You might also like
Names weve never known

Names weve never known

Man

Man

Systems of life

Systems of life

Understanding the equalization rate

Understanding the equalization rate

California grasslands and range forage grasses

California grasslands and range forage grasses

The Third Eye

The Third Eye

The trainable child

The trainable child

I Remember I Remember

I Remember I Remember

[Specimens].

[Specimens].

Corporations

Corporations

The Tiger of Mysore

The Tiger of Mysore

General Laboratory Practices and Safety (Sc4)

General Laboratory Practices and Safety (Sc4)

FDA and the Internet, Advertising and Promotion of Medical Products.

FDA and the Internet, Advertising and Promotion of Medical Products.

Middletown families

Middletown families

Pharmaceutical perspectives of cancer therapeutics by Lu, Yi Ph. D. Download PDF EPUB FB2

About this book Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics. Pharmaceutical Perspectives of Cancer Therapeutics presents a comprehensive yet easy-to-follow review of the principles, current progress and state-of-the-art of cancer therapeutics.

The complexity of cancer demands an integrated Pharmaceutical perspectives of cancer therapeutics book from both cancer biology and pharmaceutical dosage forms and drug delivery in order to warrant a successful therapeutic.

Pharmaceutical Perspectives of Cancer Therapeutics also includes cancer therapy modality in surgery, chemotherapy, and radiotherapy, as well as in combination or multi-modality, giving our book a more focused view of cancer : Springer New York.

Pharmaceutical Perspectives of Cancer Therapeutics covers a wide range of therapeutic approaches. In addition, clinical application, the development of DNA diagnosis biomarkers and cancer prevention, and the use of imaging in cancer therapy are discussed.

The use of synthetic carriers, such as lipids, polymers, and peptides for delivery and targeting of small molecules, proteins, and nucleic acids to cancer cells in vivo are discussed.

Pharmaceutical Perspectives of Cancer Therapeutics also includes cancer therapy modality in surgery, chemotherapy, and radiotherapy, as well as in combination or multi-modality, giving our.

The goal of our efforts in compiling Pharmaceutical Perspectives of Cancer Therapeutic is to produce a comprehensive yet easy-to-follow review of the principles and current approaches in this ever-growing field.

Pharmaceutical Perspectives of Cancer Therapeutics pp | Cite as Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Author: Michael D. Axelson, David E. Gerber. DESCRIPTION: Book annotation not available for this title. Title: Pharmaceutical Perspectives of Cancer Therapeutics Author: Mahato, Ram I.

(EDT)/ Lu, Yi (EDT) Publisher: Springer Verlag Publication Date: /07/07 Number of Pages: Binding Type: HARDCOVER Library of Congress: PRICE: $free shipping for all books. In contrast to conventional cancer therapeutics, novel approaches such as ligand or receptor based targeting, triggered release, intracellular drug targeting, gene delivery, cancer stem cell.

Cancer Pharmacology and Pharmacotherapy Reviewis the first book devoted entirely to providing the "must-know" facts on each cancer agent, including their pharmacokinetics, FDA-approved indications,toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review/5(4).

The Textbook of Pharmaceutical Medicine is the standard reference for everyone working and learning in pharmaceutical medicine. It is a comprehensive resource covering the processes and practices by which medicines are developed, tested and approved, and the recognised text for the Diploma in Pharmaceutical Medicine from the Faculty of Pharmaceutical.

Novel Designs of Early Phase Trials for Cancer Therapeutics provides a comprehensive review by leaders in the field of the process of drug development, the integration of molecular profiling, the changes in early phase trial designs, and endpoints to optimally develop a new generation of cancer therapeutics.

The book discusses topics such as. In a Perspectives review, Johann de Bono and Alan Ashworth take a critical look at current procedures for clinical trials in cancer. The emphasis of anticancer drug development is now firmly on Cited by: Phytochemical Aspects and Therapeutic Perspective of Cannabinoids in Cancer Treatment.

By Sanda Vladimir‐Knežević, Biljana Blažeković, Maja Bival Štefan and Marija Kindl. Submitted: September 28th Reviewed: February 6th Published: July Cited by: 1. Applications of Nanocomposite Materials in Drug Delivery Cyclodextrin-based nanosponges in drug delivery and cancer therapeutics: New perspectives for old problems.

chapter is associated with the nanocomposite microemulsions study of single-walled carbon nanotubes in arteries with applications of nanocomposite materials in drug delivery. The first part of the book discusses the fundamentals of biomaterials for cancer therapeutics. Chapters in part two discuss synthetic vaccines, proteins and polymers for cancer therapeutics.

Part three focusses on theranosis and drug delivery systems, whilst the final set of chapters look at biomaterial therapies and cancer cell interaction. Discussing recent findings, up-to-date research, and novel strategies, the book integrates perspectives from pharmacology, toxicology, and biochemistry to illustrate the potential of lysosomes in drug discovery and development.

To assess the present and future prospects for the use of co-developed companion diagnostics in drug use and development, speakers representing groups involved with test development as well as speakers representing pharmaceutical manufacturing were invited to share their perspectives.

A theme that emerged was the importance of obtaining analytical validity. The first part of the book discusses the fundamentals of biomaterials for cancer therapeutics.

Part Two discusses synthetic vaccines, proteins and polymers for cancer therapeutics. Part Three focuses on theranosis and drug delivery systems, while the final set of chapters look at biomaterial therapies and cancer cell interaction.

Of the 14 New Active Substance cancer therapeutics launched in alone, all of them were targeted therapies and 11 of them were granted Breakthrough Therapy designations by the FDA. Global spending on cancer medicines continues to rise with therapeutic and supportive care use at $ billion globally inup from $96 billion in.

The book goes on to present current therapeutic regimes including their indications and side effects, as well as their position in the international market in terms of sales and development costs. Furthermore, coverage of our advancement in the understanding of cancer biology and how this has driven the drug discovery process is clearly discussed.

For cancer therapeutics, one answer lies in how drugs are paid for. Rapidly rising drug costs have had a major impact on cancer drug development and patients with cancer, with both positive and negative outcomes.

However, this trend is clearly unsustainable and must be addressed by reengineering our collective cancer ecosystem to achieve Cited by: Title:Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson’s Disease VOLUME: 26 Author(s):Mohan Krishna Ghanta, P Elango and Bhaskar L.

V K S* Affiliation:Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra, Department of Pharmacology, Panimalar Medical College Author: Mohan Krishna Ghanta, P Elango, Bhaskar L.

V K S.